Selective PDE 2 inhibitors as pharmaceuticals for improving...

Details Selective PDE 2 inhibitors as pharmaceuticals for improving... Selective PDE 2 inhibitors as pharmaceuticals for improving...

2006-04-04

2006-04-04

Hui, San-Ming (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07022709

ABSTRACT:
The invention relates to the use of selective phosphodiesterase 2 (PDE 2) inhibitors for producing pharmaceuticals for improving perception, concentration, learning and/or memory.

REFERENCES:
patent: 5141936 (1992-08-01), Rupp et al.
patent: 6174884 (2001-01-01), Haning et al.
patent: 0771799 (1997-05-01), None
patent: 9840384 (1998-09-01), None
patent: WO 98/40384 (1998-09-01), None
Merriam-Webster's Collegiate Dictionary, 10th edition, 1998, p. 861.
Whalin et al., Molecular Pharmacology, 1991; 39(6): 711-717.
Egawa et al., Japanese Journal of Pharmacology, 1997; 75:275-281.
Merck Manuel, Home edition, 1997, pp. 12-15, 381-387, and 398-402.
Stryer, L. Biochemistry, 4thed. W.H. Freeman and Company, New York, NY, 1995.
Kandel et al., Principles of Neural Science, 3rded. Auflage, Elsevier, Kapietl , 1998, ch. 28, S. 403-408.
Martins, T., Mumby, M., Beavo, J., “Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphosiesterase from Bovine Tissues”, J. Biol Chem., 257:4, 1973-1979 (1982).
Yamamoto, T., Manganiello, V., Vaughan, M., “Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from Calk Liver”, J. Biol. Chem., 258: 20, 12526-12533 (1983).
Grant, P., Mannarino, A., Colman, R., “Purification and Characterization of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase from the Cytosol of Human Platelets”, Thrombosis Research, 59: 105-119 (1990).
Whalin, M., Strada, S., Thompson, W., “Purification and Partial Characterization of Membrane-associated Type II (cGMP-activatable) Cyclic Nucleotide Phosphodiesterase from Rabbit Brain” Biochim. Biophys. Acta., 972: 79-94 (1988).
Sonnenburg, W., Mullaney, P., Beavo, J., “Molecular Cloning of a Cyclic GMP-stimulated Cyclic Nucleotide Phosphodiesterase cDNA ”, J. of Biol. Chem., 266: 26, 17655-17661 (1991).
Tanaka, T., Hockman, S., Moos, M., Taira, M., Meacci, E., Murashima, S., Manganiello, V., “Comparison of Putative cGMP-binding Regions in Bovine Brain and Cardiac cGMP-stimulated Phosphodiesterases”, Second Messengers and Phosoproteins, 13: 87-98 (1991).
Rosman, G., Martins, T., Sonnenburg, W., Beavo, J., Ferguson, K., Loughney, K., “Isolation and Characterization of Human cDNAs Encoding a cGMP-stimulated 3', 5'-cyclic Nucleotide Phosphodiesterase”. Gene, 191: 89-95 (1997).

Affiliated with

Also associated with

Rating

Selective PDE 2 inhibitors as pharmaceuticals for improving... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selective PDE 2 inhibitors as pharmaceuticals for improving..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective PDE 2 inhibitors as pharmaceuticals for improving... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3547385